Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

<p>Supplementary Figure 1. Planned exploratory analyses by study drug for selumetinib, vistusertib and capivasertib.</p>

Saved in:
书目详细资料
主要作者: Fabrice Barlesi (15045504) (author)
其他作者: Pascale Tomasini (4354063) (author), Maryam Karimi (7168769) (author), Stefan Michiels (108030) (author), Judith Raimbourg (15033410) (author), Catherine Daniel (7119086) (author), Henri Janicot (15019596) (author), Anne Madroszyk (15033398) (author), Clarisse Audigier-Valette (15045507) (author), Elisabeth Quoix (321740) (author), Julien Mazieres (15013412) (author), Denis Moro-Sibilot (15033407) (author), Eric Dansin (5576408) (author), Olivier Molinier (15019590) (author), Hugues Morel (15033419) (author), Eric Pichon (15033425) (author), Alexis Cortot (15045510) (author), Josiane Otto (6553544) (author), François Chomy (635983) (author), Pierre-Jean Souquet (3629372) (author), Nicolas Cloarec (15045513) (author), Etienne Giroux-Leprieur (385865) (author), Ivan Bieche (15045516) (author), Ludovic Lacroix (15030059) (author), Sandrine Boyault (9337805) (author), Valery Attignon (15045519) (author), Isabelle Soubeyran (515223) (author), Alain Morel (11665966) (author), Alicia Tran-Dien (14210462) (author), Alexandra Jacquet (14952799) (author), Filippo Gustavo Dall'Olio (15045522) (author), Marta Jimenez (14952288) (author), Jean-Charles Soria (15045525) (author), Benjamin Besse (3497516) (author)
出版: 2025
主题:
Cancer
Therapeutic Research and Development
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Drug Targets
Immunotherapy
Checkpoint blockade
Lung Cancer
Precision Medicine
标签: 添加标签
没有标签, 成为第一个标记此记录!
实物特征
总结:<p>Supplementary Figure 1. Planned exploratory analyses by study drug for selumetinib, vistusertib and capivasertib.</p>

相似书籍